Atıf İçin Kopyala
Atilla E., Ataca P., Balli S., Isikoglu B., Topcuoglu P., Ozcan M., ...Daha Fazla
BLOOD, cilt.126, sa.23, ss.5459, 2015 (SCI-Expanded)
-
Yayın Türü:
Makale / Özet
-
Cilt numarası:
126
Sayı:
23
-
Basım Tarihi:
2015
-
Doi Numarası:
10.1182/blood.v126.23.5459.5459
-
Dergi Adı:
BLOOD
-
Derginin Tarandığı İndeksler:
Science Citation Index Expanded (SCI-EXPANDED), Scopus
-
Sayfa Sayıları:
ss.5459
-
Ankara Üniversitesi Adresli:
Evet
Özet
Abstract
Introduction:
Toxoplasmosis is a rare but serious and life-threatening infection following Allogeneic Stem Cell Transplantation (Allo-HSCT). The main cause of toxoplasmosis is the reactivation of latent infection in pre-transplant seropositive patients. In our study, our aim is to present toxoplasma gondii seroprevalence in our center.
Patients and Methods:
A total of 251 allogeneic stem cell transplant recipient were evaluated retrospectively from 1998 to 2015. During Allo-HSCT preparation procedures all recepients were serologically tested. Donor serology records were not adequate. Toxoplasma gondii-specific IgG and IgM antibodies were determined by Chemiluminescence by ARCHITECT lab analyzers using commercially available kits (Abbott, USA). All patients were followed for reactivation.
Results:
Toxoplasma IgG positivity was detected in 51 of patients (20.3%). There was no statistically difference detected between related or unrelated transplants. The mean age of the group was 36 (range 14-71). 144 recipients were male (57%). 208 (83%) patients were transplanted for malign hematological diseases. The majority of patients were grafted from full-matched related donors (173, 69%). The most common source of stem cell was peripheral blood in 192 patients (77%) followed by bone-marrow in 51 patients (51%), bone-marrow plus peripheral blood in 7 patients (2.8%) and cord in 1 patient (0.4%). 192 (77%) patients received myeloablative conditioning regimens. All patients received prophylactic twice weekly trimethoprim/sulfamethoxazole (TMP/SMX) (160/800mg PO daily) after engraftment. Two patients had clinical symptoms of toxoplasmosis however they were seronegative in serology. None of the patients developed an active toxoplasmosis after Allo-HSCT.
Conclusion:
Since less than 30% seropositivity defined as low rate, our institution had low rate seropositivity for Toxoplasma Gondii in Allo-HSCT recipients. Routine use of TMP/SMX prophylaxis and difficulties in diagnosis of toxoplasmosis may lead to low frequency active toxoplasmosis.
Disclosures
No relevant conflicts of interest to declare.